NASDAQ · Biotechnology · USD
YD Bio Ltd (YDES) Stock Analysis
YD Bio Ltd (YDES) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
YDES Key Statistics
As of Oct 21, 2026Trading
- Open
- $6.01
- Previous Close
- $5.84
- Day's Range
- 5.60–6.30
- 52-Week Range
- 1.70–18.66
- Volume
- 144.09K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.16
Valuation
- Market Cap
- $408.70M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 329.78
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.04
Financials (FY)
- Revenue (FY)
- $596.82K+16.94%
- Net Income (FY)
- −$8.31M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 24.67%
- Shares Outstanding
- 70.83M
- 1-Year Return
- −68.86%
Dividend and dates
- Avg Volume
- 293.59K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, YDES closed at $5.77, −68.86% over 1 year.
YD Bio Ltd (YDES) has a market capitalization of $408.70M.
In fiscal 2025, YDES reported revenue of $596.82K.
YDES Stock Return by Calendar Year
YD Bio Ltd (YDES) return since Aug 2025: what $10,000 became
- 1 year
- $10,000 $3,114
- −68.86%
- Since Aug 2025
- $10,000 $4,319
- −56.81%
If you had invested $10,000 in YD Bio Ltd (YDES) at the close on August 26, 2025, the earliest close on record here, it would have been worth $4,319 at the close on October 21, 2026: −56.81% in total, −51.73% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −52.67% |
| 2025 (partial year) | −8.76% |
As of October 21, 2026.
YDES Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $596.82K | −$8.31M | −1,392.6% |
| 2024 | $510.36K | −$1.41M | −276.6% |
| 2023 | $350.13K | $13.56K | 3.9% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $596.82K | $167.41K | −$5.27M | −$8.31M | −1,392.6% |
| 2024 | $510.36K | $155.36K | −$1.46M | −$1.41M | −276.6% |
| 2023 | $350.13K | $153.45K | −$7.12K | $13.56K | 3.9% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
YDES Valuation vs Biotechnology Median
Median of 608 stocks| Metric | YDES | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 329.78 | 13.30 | 24.8x the median |
| Profit margin | 24.67% | −38.31% | 63.0 pts above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B